Compare Mesoblast Limited (MESO) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Walmart Stores Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Walmart Stores Inc trades at $111.35 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 501.2× Mesoblast Limited's market cap, and Walmart Stores Inc pays a 0.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Walmart Stores Inc for 101 Days on average.
| MESO | WMT | |
|---|---|---|
Market Cap | $1.75B | $877.15B |
Volume | 239,027 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $134.20 |
52-Week Low | $13.19 | $100.61 |
Typical Hold Time | 15 Days | 101 Days |
Enterprise Value | $1.83B | $939.38B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Walmart (WMT) trades at $110.56, up 2.27% with a bullish technical signal. The company demonstrates strong fundamentals with revenue reaching $680.99B in 2025 and consistent earnings beats. Recent news highlights expansion in AI capabilities, Marketplace growth exceeding 50%, and new Medicare Advantage partnerships. The stock trades at a P/E of 40.06 and P/S of 1.2, reflecting premium valuation amid solid operational performance.
Walmart presents a compelling growth story with expanding digital services and market share gains. The primary investment opportunity lies in continued e-commerce momentum and operational efficiency. Key risks include valuation sensitivity, rising costs, and consumer spending pressures. Analyst consensus remains strongly bullish with a $128.84 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
